Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Helus Pharma Touts Positive Data for Depression Drug

Helus Pharma Inc. (NASDAQ:HELP) reported topline results from its pivotal Phase 3 APPROACH trial, showing its novel serotonergic agonist HLP003 rapidly and durably reduced symptoms in adults with major depressive disorder . Chief Executive Officer Michael Halstead said patients with persistent depression symptoms face a major unmet need for fast-acting, well-tolerated adjunctive therapies.…

Helus Pharma Touts Positive Data for Depression Drug

We haven't written up this one. Benzinga has the full story — the link below goes straight to it.

Read the original at benzinga.com →

More in Finance & Markets

More from Monday 16 November →